Abstract
Thirteen acute psychotic patients received continuous oral treatment with perphenazine for a period of 8 weeks. Blood samples for quantification of perphenazine, perphenazine sulphoxide and prolactin were drawn twice weekly. Simultaneously, the therapeutic outcome and the degree of extrapyramidal side effects were recorded. The following conclusions were made:
-
1.
In accordance with results achieved in one of our earlier investigations, a high risk of provoking extrapyramidal side effects was associated with plasma levels of perphenazine exceeding about 3 nmol/l.
-
2.
An excellent therapeutic outcome was associated with plasma concentrations of perphenazine above 1.5 nmol/l.
-
3.
Plasma concentrations of perphenazine and prolactin were poorly correlated to each other (R=0.49).
-
4.
A significant correlation (R=0.85) was shown between the scores for the Brief Psychiatric Rating Scale and the Comprehensive Psychopathological Rating Scale.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Åsberg M, Montgomery SA, Perris C, Schalling D, Sedvall G (1978) A comprehensive psychopathological rating scale. Acta Psychiatr. Scand (Suppl) 271:5–42
Bolvig Hansen L, Elley J, Christensen TLR, Larsen NE, Naestoft J, Hvidberg EF (1979) Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. Br J Clin Pharmacol 7:75–80
Bolvig Hansen L, Larsen NE (1977) Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 53:127–130
Brodie BB (1964) Distribution and fate of drugs in Binns. In: Livingstone E, Livingstone S (eds) Absorption and distribution of drugs. McMillan, Edinburgh, pp 199–251
Buyze G, Egberts PFC, Muunsze RG, Poslavska A (1973) Blood levels of thioridazine and some of its metabolites in psychiatric patients. A preliminary report. Psychiatr Neurol Neurochir 76:229–239
Cooper TB (1978) Plasma level monitoring of antipsychotic drugs. Clin Pharmacokinet 3:14–38
Cooper TB, Simpson GM, Lee JH (1976) Thymoleptic and neuroleptic drug plasma levels in psychiatry: Current status. Int Rev Neurobiol 19:269–309
Curry SH (1968) Method for the estimation of nanogram quantities of chlorpromazine and some of its relatively non-polar metabolites in plasma, using gas chromatography with an electron capture detector. Anal Chem 40:1251–1255
Davis JM, Janowska DS, Sekerti HJ, Manier D, El-Yousef MK (1974) The pharmacokinetics of butaperazine in serum. In: Forrest IS, Carr CJ, Usdin E (eds) Phenothiazines and structurally related drugs. Raven Press, New York, pp 433–443
Kolakowska T, Orr M, Gelder M, Heggie M, Wiles D, Franklin M (1979) Clinical significance of plasma drug and prolactin levels during acute chloropromazine treatment: A replication. Br J Psychiatry 135:352–359
Larsen NE (1981) Evaluation of existing methods for quantitation of neuroleptics — in relation to the clinic. In: Usdin E, Dahl S, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry. McMillan, London (in press)
Larsen NE, Naestoft J (1975) Determination of perphenazine and its sulphoxide metabolite in human plasma after therapeutic doses by gas chromatography. J Chromatogr 109:259–264
Mackay AVP, Healey AF, Baker J (1974) The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics. Br J Clin Pharmacol 1:425–430
May RA, van Putten T (1978) Plasma levels of clorpromazine in schizophrenics. Arch Gen Psychiatry 35:1081–1087
Mjorndal T, Oreland L (1971) Determination of thioxanthenes in plasma at therapeutic concentrations. Acta Pharmacol Toxicol 29:295–302
Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812
Reuter AM, Kennes F, Gevaert Y, Franchimont P (1976) Homologos radioimmunoassay for human prolactin. Int J Nucl Med Biol 3: 21–28
Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (Suppl) 212:11–25
Wiles DH, Franklin M (1978) Radioimmunoassay for fluphenazine in human plasma. Br J Clin Pharmacol 5:265–268
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hansen, L.B., Larsen, NE. & Vestergård, P. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology 74, 306–309 (1981). https://doi.org/10.1007/BF00432736
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00432736